Moderna Lifts Outlook, Swings to 3Q Profit
By Connor Hart
Moderna raised its full-year outlook as it swung to a profit and logged higher revenue in the recent quarter, boosted in part by stabilizing demand for its Covid-19 vaccine.
Shares were up 9.6% to $264.79 in premarket trading.
The biopharmaceutical company said Friday it now expects total revenue growth of 15% to 25% for the year, compared with a previous outlook for up to 10% growth. It continues to expect roughly half of its revenue to come from the U.S. and half from international markets.
The higher outlook follows the U.S. approval of mFLUSIVA, the company's mRNA-based influenza vaccine, as well as what Chief Executive Stephane Bancel called positive late-stage trial results of intismeran, an investigational cancer therapy being jointly developed by Moderna and Merck.
"Looking ahead, we anticipate additional intismeran readouts, pivotal data in propionic acidemia and further regulatory approvals as we advance our pipeline and build a more diversified company," Bancel said.
Moderna swung to a third-quarter profit of $162 million from a loss of $200 million a year earlier. Quarterly earnings came out to 38 cents a share, compared with analyst expectations for a loss of $1.10 a share, according to FactSet.
Total revenue climbed 29% to $1.31 billion, ahead of Wall Street estimates for $890.3 million. The company attributed the increase to higher Covid-19 vaccine sales in international markets, as well as deliveries made under long-term government partnerships.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
November 06, 2026 07:37 ET (12:37 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for November
3 of the Best Dividend Stocks to Own
The 10 Best Companies to Invest in Now
These Overvalued Stocks Have Plenty of Room to Fall
United States